$1.00
Xinlilai (Ascletis) Ravidasvir Hydrochloride Tablets deliver 200?mg per tablet, 14 tablets per bottle. Manufactured by Ascletis Pharma, approved under NMPA H20200008. Investigated as an NS5A inhibitor in Hepatitis C virus (HCV) research.
?? For research use only. Not intended for human or veterinary treatment.?Please consult staff for other specifications and uses?
Ravidasvir Hydrochloride is a novel NS5A inhibitor under study for its antiviral effects against Hepatitis C Virus (HCV). It is primarily investigated in combination with other agents such as sofosbuvir for pan-genotypic antiviral research. This product is provided in tablet form for experimental modeling of HCV replication, resistance profiling, and antiviral screening.
Manufactured by Ascletis Pharma (Zhejiang) Co., Ltd., this formulation is regulated under NMPA approval number H20200008. The compound shows promise in studies targeting genotype 1-6 HCV RNA.
| Parameter | Details |
|---|---|
| Product Name | Ravidasvir Hydrochloride Tablets (Xinlilai / Ascletis) |
| Generic Name | Ravidasvir Hydrochloride |
| CAS Number | 1448757-44-1 |
| Molecular Formula | C??H??ClN?O? |
| Molecular Weight | ~758.3?g/mol |
| Dosage Form | Oral tablets |
| Strength | 200 mg per tablet |
| Quantity | 14 tablets per bottle |
| Approval No. | H20200008 |
| Drug Code | 86981008000028 |
| Manufacturer | Ascletis Pharma (Zhejiang) Co., Ltd. |
| Barcode | 6973125730005 |
| Storage Conditions | Store below 25?°C, dry and sealed |
| Intended Use | Laboratory use in antiviral and HCV research only |
Ravidasvir Hydrochloride is a potent NS5A replication complex inhibitor. It disrupts the replication and assembly of HCV RNA by targeting the NS5A protein domain, making it a key candidate in pan-genotypic antiviral research, especially in combination with sofosbuvir.
Hepatitis C Virus (HCV) inhibition modeling
Resistance testing in NS5A mutant strains
Antiviral pharmacokinetics and in vitro potency studies
Combination therapy research with DAAs (Direct-Acting Antivirals)
Liver cell line HCV propagation and clearance studies
Use only in approved laboratory facilities
Use standard protective equipment (gloves, goggles, coat)
Not for ingestion, inhalation, or injection
Dispose in accordance with lab waste guidelines
Not for human clinical or diagnostic use
ravidasvir hydrochloride tablets, ravidasvir CAS 1448757-44-1, Xinlilai Ascletis tablets, NS5A inhibitor research, HCV antiviral compound, wholesale ravidasvir tablets, H20200008, experimental hepatitis C drug
This product is provided exclusively for scientific research and laboratory applications. It is not approved for therapeutic, clinical, or diagnostic use in humans or animals. Misuse may carry regulatory and health risks. Use under institutional protocols only.
| 重量 | 1 公斤 |
|---|---|
| 尺寸 | 26 × 23 × 26 厘米 |
A1: CAS 1448757-44-1, confirming its structure and identity.
A2: No. This product is intended only for research use in laboratories and institutions.
A3: Yes, both bulk and retail orders are supported with international shipping.
A4: Yes, we can provide COA (Certificate of Analysis) and SDS (Safety Data Sheet) upon request.
A5: In research, it is often studied in combination with sofosbuvir for enhanced antiviral effect.
A6: It has demonstrated pan-genotypic (genotypes 1-6) activity in HCV replication models.
Select at least 2 products
to compare
Limertinib Tablets 80?mg ×?20 – by Osscon Pharma | Research Use Only (3rd?Gen EGFR?TKI) 
Adenosylcobalamin Capsules 0.5mg (Cobamamide Capsules) – AR Grade Factory low price wholesale 
评价
目前还没有评价